ADX47273 is a selective positive allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). It has been investigated primarily for its potential therapeutic applications in neurological and psychiatric disorders. Research suggests it may enhance cognitive function and synaptic plasticity, making it a candidate for the treatment of conditions such as schizophrenia, particularly for improving cognitive and negative symptoms that are not adequately addressed by current antipsychotics. It has also shown potential in preclinical models for improving deficits in learning and memory. Due to its mechanism of modulating glutamate signaling—a key neurotransmitter system involved in excitatory synaptic transmission—ADX47273 is of interest in developing novel treatments for neurodegenerative diseases and other disorders involving glutamatergic dysfunction. However, it remains primarily a research compound and has not reached clinical use.